Advertisement
The Radical-7 Pulse CO-Oximeter from Masimo Corporation continuously andnon-invasively measures blood constituents in patients without having to drawblood. The device uses multiple wavelengths of light in a single, simple toapply sensor. It can be used reliably in different care settings, for exampleat the patient's bedside or during transport.
Advertisement
In addition to its unique use of algorithms to ensure accurate patientmonitoring, the Radical-7 includes a unique technology platform that allowsfor additional features to be added as simple software upgrades.
In congratulating the winner, Anne Trimmer, MTAA CEO, said: "Masimo'sOximeter is an excellent example of innovation in the medical technologysector. It benefits the patient, the clinician and the health system."
The Kerrin Rennie Award for Excellence in Medical Technology -- ImprovingQuality of Life recognises the innovative and extraordinary contribution ofmedical technology in improving health outcomes of Australian patients.
The award dinner was held as part of a two-day conference on medicaltechnology from Wednesday 24 - Thursday 25 September at Star City in Sydney.Companies could enter products launched in Australia between 1 January 2007and 1 August 2008 used in the diagnosis, prevention, treatment or managementof disease and disability. Entries were judged by an independent panel.
The other finalists are:
Ex-Press Shunt -- Device Technologies
The Ex-Press miniature glaucoma shunt is an implant used to drain offexcess fluid in the eye and to reduce intraocular pressure. The device createsa permanent pathway for excess fluid to drain from the eye and maintains amore normal pressure in the eye. The Ex-Press Shunt is an improved technologythat causes less post operative trauma and fewer adverse events.
HCO 1100 Protein Permeable Membrane -- Gambro
The HCO 1100 Protein-Permeable Membrane is designed to improve thetreatment of multiple myeloma patients with acute renal failure by removinglarger molecules from blood particularly serum Free Light Chains (FLC), theprotein present at abnormally high concentrations in this patient group. Highlevels of FLCs in the blood circulating through the kidney present a majorcause of renal impairment. This new membrane technology in combination withchemotherapy can prevent the patient from developing end stage renal diseaseand having to rely on dialysis for survival.
The Medical Technology Association of Australia (MTAA) is the nationalpeak industry body representing companies in the medical technology industry.MTAA aims to ensure the benefits of modern, innovative and reliable medicaltechnologyare delivered to the community for a healthier Australia.http://www.mtaa.org.au
Media contact: Marion Demann MTAA 0416 625 678
SOURCE The Medical Technology Association of Australia
